James Newby, MD
Family Medicine · Norfolk, VANPI 1265524813
Payments from drug & device makers
Across 502 payments — averaging $17.67 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$1K
- Novo Nordisk$1K
- Boehringer Ingelheim$929
- Lilly USA, LLC$803
- Bayer$476
- Amgen$357
- plus $4K from 28 others
What the payments were for
- Food & beverage$8,80799%
- Education$651%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 82 | $1,470 |
| Novo Nordisk | 68 | $1,040 |
| Boehringer Ingelheim | 51 | $929 |
| Lilly USA, LLC | 48 | $803 |
| Bayer | 27 | $476 |
| Amgen | 21 | $357 |
| Novartis | 20 | $351 |
| Sanofi-aventis U.S. LLC | 19 | $330 |
| Insulet Corporation | 12 | $315 |
| Pfizer | 19 | $308 |
| Amarin Pharma, Inc. | 17 | $292 |
| Abbott | 11 | $252 |
| Corcept Therapeutics | 12 | $219 |
| Merck | 13 | $218 |
| GSK | 14 | $206 |
| Astellas Pharma US Inc | 6 | $165 |
| Esperion Therapeutics, Inc. | 9 | $164 |
| AbbVie | 8 | $154 |
| Xeris Pharmaceuticals, Inc. | 6 | $125 |
| Medtronic(2 entities) | 6 | $97 |
| E.r. Squibb & Sons, L.L.C. | 5 | $85 |
| Dexcom, Inc. | 4 | $81 |
| Johnson & Johnson | 4 | $69 |
| Biogen | 3 | $58 |
| Seqirus USA Inc | 3 | $53 |
| Exact Sciences | 2 | $45 |
| Bioventus LLC | 2 | $45 |
| Corium, LLC | 2 | $35 |
| Arbor Pharmaceuticals, Inc. | 2 | $34 |
| Kowa Pharmaceuticals America, Inc. | 2 | $27 |
| Viatris Specialty LLC | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $18 |
| Hikma Pharmaceuticals USA | 1 | $15 |
| Watermark Medical, Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Omnipod$106
How this compares
$8,872 in reported general payments places this provider in the 90th percentile of 2,553 family medicine providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 103 | $143,705 |
| EliquisApixaban | 166 | $139,402 |
| FarxigaDapagliflozin Propanediol | 97 | $92,001 |
| JardianceEmpagliflozin | 71 | $74,682 |
| TrulicityDulaglutide | 28 | $47,115 |
| LinzessLinaclotide | 42 | $39,085 |
| XareltoRivaroxaban | 43 | $35,566 |
| RybelsusSemaglutide | 24 | $33,877 |
| Omnipod Dash Pods (Gen 4)Insulin Pump Cart,cont Inf,bt | 28 | $27,803 |
| EntrestoSacubitril/Valsartan | 13 | $20,523 |
| Tresiba Flextouch U-200Insulin Degludec | 28 | $20,147 |
| Risperdal ConstaRisperidone Microspheres | 17 | $18,335 |
| Janumet XrSitagliptin Phos/Metformin Hcl | 12 | $16,201 |
| Spiriva RespimatTiotropium Bromide | 21 | $13,849 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $11,114 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus, Novolog | $1,040 | $183,097150 claims |
| PfizerEliquis | $308 | $139,402166 claims |
| AstraZenecaFarxiga | $1,470 | $92,00197 claims |
| Boehringer IngelheimJardiance, Spiriva Respimat | $929 | $88,53292 claims |
| Johnson & JohnsonXarelto, Risperdal Consta | $69 | $53,90160 claims |
| Lilly USA, LLCTrulicity, Humalog | $803 | $50,19439 claims |
| AbbVieLinzess | $154 | $39,08542 claims |
| NovartisEntresto | $351 | $20,52313 claims |
| MerckJanumet Xr | $218 | $16,20112 claims |
| GSKBreo Ellipta, Incruse Ellipta | $206 | $11,11128 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,553 family medicine providers in Virginia.
Other family medicine in Norfolk
- Monique MatuskowitzNorfolk$110K
- Aaron HartmanMidlothian$17.4M
- John ScottGlen Allen$16.7M
- Banu MyneniPortsmouth$12.8M
- Patricia HouserWinchester$3.5M
- Stephan JannachDanville$3M
- Linda SchneiderHampton$2.1M
- Jennifer BrownMidlothian$1.3M
- Brian McCormickHampton$793K
- Jerome DanielNorth Chesterfield$779K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.